MedTrace Logo

BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab

NCT03486301 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 87

Last updated 2025-11-12

No results posted yet for this study

Summary

Phase 1 Open-Label Dose Escalation Study of BDB001 as a Single Agent and in combination with Pembrolizumab in Subjects with Advanced Solid Tumors

Conditions

  • Tumor, Solid

Interventions

DRUG

BDB001 (EIK1001)

BDB001 (EIK1001) is an immunotherapy agent.

DRUG

Pembrolizumab

Pembrolizumab is a potent humanized monoclonal antibody with high specificity of binding to the PD 1 receptor. Pembrolizumab has an acceptable preclinical safety profile and is approved as an IV therapy for a variety of advanced malignancies.

Sponsors & Collaborators

Principal Investigators

  • Harry Raftopoulos, MD · Eikon Therapeutics

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-15
Primary Completion
2024-03-31
Completion
2024-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03486301 on ClinicalTrials.gov